Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

Once-monthly efimosfermin demonstrated statistically significant fibrosis improvement ≥1 stage without worsening of MASH vs. placebo after 24-weeks of treatment Two-thirds of efimosfermin-treated ...

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...

Ovid Therapeutics is pumping the brakes on a planned phase 2 trial for its ROCK2 inhibitor in a type of brain lesion while it considers any lessons to be learned from the mixed readout of Recursion’s ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial ...

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory ...